ACETAMINOPHEN; CODEINE PHOSPHATE - Generic Drug Details

What are the generic sources for acetaminophen; codeine phosphate and what is the scope of patent protection?

Acetaminophen; codeine phosphate is the generic ingredient in seventeen branded drugs marketed by Teva, Robins Ah, Solvay, Ortho Mcneil Pharm, Actavis Mid Atlantic, Chartwell, Chartwell Molecular, Dava Pharms Inc, Genus Lifesciences, Pai Holdings, Pharmobedient, Strides Pharma, Valeant Pharms Llc, Able, Am Therap, Amneal Pharms Ny, Ani Pharms, Aurolife Pharma Llc, Duramed Pharms Barr, Elite Labs Inc, Everylife, Fosun Pharma, Halsey, Hibrow Hlthcare, Kv Pharm, Lederle, Mikart, Mutual Pharm, Puracap Pharm, Purepac Pharm, Rhodes Pharms, Roxane, Sandoz, Specgx Llc, Strides Pharma Intl, Sun Pharm Inds Ltd, Superpharm, Usl Pharma, Valeant Pharm Intl, Vitarine, Warner Chilcott, Watson Labs, Watson Labs Florida, Whiteworth Town Plsn, Carnrick, Glaxosmithkline, Vangard, and Janssen Pharms, and is included in one hundred and eight NDAs. Additional information is available in the individual branded drug profile pages.

Twenty-four suppliers are listed for this compound.

Summary for ACETAMINOPHEN; CODEINE PHOSPHATE

US Patents:	0
Tradenames:	17
Applicants:	48
NDAs:	108
Finished Product Suppliers / Packagers:	24
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	1
DailyMed Link:	ACETAMINOPHEN; CODEINE PHOSPHATE at DailyMed

Recent Clinical Trials for ACETAMINOPHEN; CODEINE PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roxane Laboratories	Phase 1

See all ACETAMINOPHEN; CODEINE PHOSPHATE clinical trials

Pharmacology for ACETAMINOPHEN; CODEINE PHOSPHATE

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ACETAMINOPHEN; CODEINE PHOSPHATE

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

US Patents and Regulatory Information for ACETAMINOPHEN; CODEINE PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Elite Labs Inc	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	TABLET;ORAL	212418-001	Sep 10, 2019	AA	RX	No	No
Able	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	TABLET;ORAL	040452-001	Aug 1, 2002		DISCN	No	No
Usl Pharma	ACETAMINOPHEN AND CODEINE PHOSPHATE	acetaminophen; codeine phosphate	TABLET;ORAL	087920-001	Jun 22, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Acetaminophen; Codeine Phosphate

Last updated: February 14, 2026

Market Overview

Acetaminophen combined with codeine phosphate, commonly marketed as Tylenol #3, remains a prescription analgesic. The drug is indicated for moderate pain relief and cough suppression but is subject to evolving regulation due to concerns over abuse potential. Its market presence is influenced by regulatory restrictions, alternative therapies, and ongoing patent and formulation developments.

Key Market Drivers

• Regulatory Environment: Governments worldwide are tightening controls on opioids, impacting availability. The US Drug Enforcement Administration (DEA) classifies combination drugs with codeine as Schedule III, with some jurisdictions moving toward Schedule II or tightening prescription controls [1]. Similar policies occur in Europe, Canada, and Australia, reducing prescription volumes.

• Consumer Preferences: Growing preference for opioid-sparing analgesics drives demand for non-opioid alternatives, impacting sales of combination products.

• Pharmaceutical Industry Trends: Drug developers explore reformulations with lower abuse potential, including non-opioid combinations or abuse-deterrent formulations.

• Healthcare Trends: Emphasis on responsible prescribing practices and opioid stewardship programs influences prescription frequency.

Market Size and Revenue Trends

• Global Market Size: Estimated at approximately USD 1.2 billion in 2022 for acetaminophen-codeine formulations, with North America accounting for nearly 60% of sales [2].

• Historical Revenue Growth: Post-2010, the market experienced compound annual growth rates (CAGR) of approximately 3%, driven by increasing analgesic demand.

• Recent Impact of Regulation: From 2018 onward, growth slowed due to stricter regulations, with some markets witnessing declines of up to 10% annually.

Regional Market Dynamics

Region	Market Size (USD millions, 2022)	Growth Rate (2020-2022)	Regulatory Impact
North America	720	1-2%	Tightening prescription controls; increased abuse concerns
Europe	250	0-1%	Stricter prescription guidelines
Asia-Pacific	150	5-7%	Growing demand, underpenetrated markets
Latin America	80	2-3%	Emerging markets, less strict regulation

Market Trends and Innovations

• Formulation Development: Focus on abuse-deterrent formulations, including tamper-resistant tablets and combination with non-opioid agents.

• Generic Penetration: High prevalence of generic formulations limits revenue for branded drugs.

• Potential Market Exit: Some pharmaceutical companies withdraw or limit production due to regulatory constraints, affecting supply chains and market stability.

Competitive Landscape

Major players include Johnson & Johnson (Tylenol #3), Endo Pharmaceuticals, and local generic manufacturers. Market share is consolidating with emerging entrants focusing on non-opioid substitutes.

Financial Trajectory Forecast

• Revenue Projections: Expected to decline at a CAGR of 2-3% over the next five years, primarily due to increased regulation and decreasing prescription volumes in mature markets.

• Emerging Markets: Will experience growth at 4-6%, driven by expanding healthcare infrastructure and lesser regulatory restrictions.

• Impact of Patent and Formulation Changes: Limited, as most formulations are off-patent; innovation resides in abuse-deterrent technologies.

Regulatory and Policy Outlook

• US: Ongoing discussions on classifying combination products with codeine as Schedule II due to abuse potential.

• Europe: Stricter prescription surveillance and dose restrictions.

• Canada & Australia: Implementing tamper-resistant formulations and stricter prescribing guidelines.

Potential policy shifts could accelerate decline in certain markets, especially North America and Europe.

Key Considerations for Stakeholders

• Investors: Monitor regulatory policies closely; declining market sizes may pressure revenues.

• Manufacturers: Focus on reformulations and abuse-deterrent technologies for market share retention.

• Developers: Explore non-opioid combinations and alternative analgesic compounds.

Key Takeaways

• The market for acetaminophen-codeine phosphate faces headwinds from regulatory tightening and growing preference for non-opioid therapies.
• The global market is projected to decline slightly overall, with growth confined to emerging regions.
• Innovation centers on abuse deterrence and reformulation to sustain market relevance.
• Regulatory developments will heavily influence future market dynamics and financial outcomes.
• The market's future depends on regulatory policies, healthcare adoption of alternative therapies, and technological innovation.

FAQs

1. How do regulatory changes impact the sales of acetaminophen-codeine products?
   Increased restrictions on opioid prescriptions, scheduling class changes, and prescription monitoring programs reduce dispensing volumes, negatively affecting sales.

2. What are the emerging alternatives to acetaminophen-codeine formulations?
   Non-opioid analgesics like NSAIDs, acetaminophen alone, and new biologics or small molecules with pain-relief capabilities.

3. Which regions present the highest growth opportunities?
   Asia-Pacific and Latin America are expanding markets due to rising healthcare access and less restrictive regulatory environments.

4. How does abuse-deterrent formulation development influence the market?
   It allows companies to sustain or extend product viability, meet regulatory standards, and appeal to prescribers concerned about opioid abuse.

5. What are the main factors driving the market decline in mature regions?
   Stricter prescribing policies, societal pushback against opioid abuse, and the availability of safer alternative medications.

Citations

[1] DEA Scheduling and Regulations, U.S. Drug Enforcement Administration, 2022.
[2] Global Analgesic Market Data, IQVIA, 2022.